Quarterly report pursuant to Section 13 or 15(d)

Balance Sheets

v3.20.2
Balance Sheets - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets    
Cash $ 6,214,337 $ 6,835
Deferred offering costs 42,580
Total current assets 6,256,917 6,835
Acquired patents, net 17,130 19,836
Total assets 6,274,047 26,671
Current liabilities    
Accounts payable & accrued interest 800,219 730,309
Accrued offering costs 42,580
Unreimbursed Expenses 138,009 11,626
Advance from related party/shareholder 635,154 635,154
Total current liabilities 1,615,962 1,377,089
Total liabilities 1,615,962 1,377,089
Stockholders' equity (deficit)    
Common stock, $0.001 par value; 100,000,000 shares authorized; 11,970,185 and 8,458,048 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 11,970 8,458
Preferred stock value
Additional paid-in capital 32,572,042 25,853,134
Accumulated deficit (27,925,927) (27,213,991)
Total stockholders' equity (deficit) 4,658,085 (1,350,418)
Total liabilities and stockholders' equity 6,274,047 26,671
Series A Preferred Stock [Member]    
Stockholders' equity (deficit)    
Preferred stock value 1,521
Series B Preferred Stock [Member]    
Stockholders' equity (deficit)    
Preferred stock value 129
Series C Preferred Stock [Member]    
Stockholders' equity (deficit)    
Preferred stock value 67
Series D Preferred Stock [Member]    
Stockholders' equity (deficit)    
Preferred stock value $ 264